Ocugen, Inc. Form 10-Q Summary
Business Context and Reporting Period
Ocugen, Inc. is a biotechnology company developing gene and cell therapies and vaccines. The company operates as one segment and has not generated significant revenue. This unaudited quarterly report covers the three and six months ended June 30, 2022, filed August 5, 2022.
- Key programs include COVAXIN, OCU400 and OCU410 modifier gene therapies, OCU200, and the NeoCart cell therapy platform.
- COVAXIN rights cover the United States, Canada, and Mexico under agreements with Bharat Biotech. COVAXIN has WHO Emergency Use Listing and active adult emergency authorization in Mexico, but U.S. and Canadian commercialization remained subject to regulatory approval.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | No significant revenue reported | No significant revenue reported |
| Research and development expense | $9.0 million | $16.9 million |
| General and administrative expense | $10.6 million | $20.7 million |
| Total operating expenses | $19.6 million | $37.6 million |
| Net loss | $19.5 million | $37.5 million |
| Net loss per share | $0.09 | $0.18 |
| Net cash used in operating activities | Not separately provided | $28.9 million |
- Cash and cash equivalents were $115.0 million at June 30, 2022, compared with $95.0 million at December 31, 2021.
- Total assets were $130.1 million, total liabilities were $16.0 million, and stockholders’ equity was $114.1 million at June 30, 2022.
- Debt consisted primarily of $1.75 million of net EB-5 borrowings. Accounts payable and accrued expenses totaled approximately $10.0 million.
- Net cash used in investing activities was $1.6 million, primarily for property and equipment. Net cash provided by financing activities was $50.3 million.
- The company had an accumulated deficit of $169.2 million. Operating margins and profitability metrics are not meaningful because the company has no significant revenue and incurred operating losses.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense decreased $9.8 million, primarily because the prior-year period included a $15.0 million upfront payment to Bharat Biotech for Canadian rights. This decrease was partly offset by higher employee, COVAXIN, OCU200, and OCU400 development costs.
- Second-quarter general and administrative expense increased $3.8 million due mainly to higher employee costs, new headquarters expenses, professional and legal fees, and pre-commercialization activities.
- Second-quarter net loss improved by $6.5 million from $26.0 million to $19.5 million, largely reflecting the absence of the prior-year COVAXIN upfront payment.
- For the six-month period, total operating expenses increased $4.9 million and net loss increased $4.5 million compared with 2021. Research and development expense declined $4.8 million, while general and administrative expense increased $9.7 million.
- February 2022 financing generated $49.8 million of net proceeds from the issuance of 16.0 million common shares. In June 2022, the company established an at-the-market program permitting sales of up to $160.0 million of common stock; no shares had been sold under the program as of June 30, 2022.
- Common shares outstanding increased to approximately 216.1 million at June 30, 2022 from approximately 199.4 million at December 31, 2021.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects existing cash to fund operations into the second quarter of 2023, but states that cash will not meet capital requirements over the following 12 months. The filing identifies substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Additional capital will be required through potential equity or debt offerings, strategic arrangements, asset sales, grants, licensing, or collaborations. Failure to obtain funding could require the company to delay, scale back, or eliminate programs, pursue strategic alternatives, or cease operations.
- The COVAXIN Phase 2/3 U.S. immuno-bridging and broadening trial was enrolling and dosing adults. The company planned an additional adult safety trial to support a potential BLA. The FDA declined the company’s pediatric EUA request in March 2022.
- Health Canada issued a Notice of Deficiency on the COVAXIN submission; the company’s responses remained under review. Mexico’s adult authorization remained active, while the pediatric submission was under review.
- Technology transfer and manufacturing preparation for COVAXIN with Jubilant HollisterStier were in progress. The company committed to purchase approximately $14.3 million of COVAXIN drug product components from Bharat Biotech, with the existing Series B preferred stock advance applied to the commitment.
- OCU400 completed dosing in its first clinical cohort, and the independent Data Safety Monitoring Board recommended proceeding to the second cohort, expected to begin in August 2022. The company intended to initiate OCU410 and OCU200 clinical trials in 2023, subject to development and regulatory progress.
- Material risks include clinical and regulatory failure or delay, manufacturing and supply dependence on third parties, uncertain market demand, intellectual property challenges, dilution from future financing, COVID-19 and geopolitical disruptions, and the company’s continuing losses and cash requirements.
- Two consolidated securities class actions and consolidated shareholder derivative litigation were pending. The company believes the claims are without merit; no loss was accrued because a probable and reasonably estimable loss had not been identified.
- As of June 30, 2022, the filing reported no material changes to previously disclosed risk factors, no off-balance-sheet arrangements, and effective disclosure controls and procedures.
Important Facts for Investors to Verify
- Whether COVAXIN obtains required U.S. and Canadian regulatory approvals and whether the Mexican commercialization opportunity produces revenue.
- The timing, enrollment, safety results, and regulatory significance of the COVAXIN adult trials and the status of Health Canada’s deficiency review.
- Actual cash burn, additional financing needs, and the company’s ability to extend liquidity beyond the second quarter of 2023 without excessive dilution or unfavorable terms.
- Progress and clinical data for OCU400, OCU410, OCU200, and NeoCart, including the timing of planned trials.
- The outcome and potential financial exposure from the pending securities and derivative litigation.
- Execution of COVAXIN manufacturing technology transfer, supply commitments, and the impact of Bharat Biotech and other third-party dependencies.